Note: Single-source report; awaiting corroboration.
Researchers at the National Institutes of Health have identified detailed intracellular processes linked to the weight-loss effects of GLP-1 receptor agonists like semaglutide. Using fluorescence imaging in mouse brain tissue, the study found that increased levels of cyclic adenosine monophosphate (cAMP) in the area postrema—a brain region controlling appetite—are critical for the drug's effects.
The research showed that neuron cAMP responses to semaglutide differ, with some neurons sustaining elevated levels and others showing only transient increases, possibly due to receptor internalization or degradation. This variability may explain differences in patient responses and why weight-loss effects eventually plateau.
Additionally, by inhibiting PDE4—the enzyme that degrades cAMP—using the drug roflumilast, researchers were able to sustain cAMP signaling in neurons. This suggests a possible approach to enhance or prolong GLP-1 drug effects.
These findings provide new insights into how intracellular signaling mechanisms shape GLP-1-induced weight loss and may inform future strategies to improve treatment outcomes.